|
STUB1 |
STIP1 homology and U-box containing protein 1 |
- Downregulation of TGF-beta receptor signaling
- RIPK1-mediated regulated necrosis
- Regulation of TNFR1 signaling
- Regulation of necroptotic cell death
- Downregulation of ERBB2 signaling
- Regulation of RUNX2 expression and activity
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
SYK |
spleen associated tyrosine kinase |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- FCGR activation
- FCGR activation
- Regulation of actin dynamics for phagocytic cup formation
- Role of phospholipids in phagocytosis
- DAP12 signaling
- Fc epsilon receptor (FCERI) signaling
- Fc epsilon receptor (FCERI) signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Integrin signaling
- CLEC7A (Dectin-1) signaling
- Dectin-2 family
- Dectin-2 family
- Interleukin-2 signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- FCGR3A-mediated IL10 synthesis
- FCGR3A-mediated phagocytosis
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- FLT3 signaling through SRC family kinases
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Staurosporine
- N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
- Tamatinib
- 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
- 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
- Ellagic acid
- Fostamatinib
- Entospletinib
|
|
|
TEC |
tec protein tyrosine kinase |
- Signaling by SCF-KIT
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- Interleukin-3, Interleukin-5 and GM-CSF signaling
|
- Fostamatinib
- Zanubrutinib
|
|
|
TNFRSF1A |
TNF receptor superfamily member 1A |
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- TNFR1-mediated ceramide production
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- TNF signaling
|
- 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
- Tasonermin
|
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
|
|
TOP1 |
DNA topoisomerase I |
- SUMOylation of DNA replication proteins
|
- Irinotecan
- Dactinomycin
- Doxorubicin
- Topotecan
- Camptothecin
- Edotecarin
- Lucanthone
- Elsamitrucin
- 7-ethyl-10-hydroxycamptothecin
- Sodium stibogluconate
- Cositecan
- XMT-1001
- Rubitecan
- 2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM
- 4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE
- Hexylresorcinol
- Sacituzumab govitecan
- Trastuzumab deruxtecan
|
|
|
TSHR |
thyroid stimulating hormone receptor |
- Hormone ligand-binding receptors
- G alpha (s) signalling events
|
|
- Congenital nongoitrous hypothyroidism (CHNG)
|
|
TTC3 |
tetratricopeptide repeat domain 3 |
|
|
|
|
TYK2 |
tyrosine kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Other interleukin signaling
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Potential therapeutics for SARS
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Signaling by ALK fusions and activated point mutants
- Evasion by RSV of host interferon responses
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Deucravacitinib
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|
|
USP6 |
ubiquitin specific peptidase 6 |
|
|
|
|
VNN2 |
vanin 2 |
- Post-translational modification: synthesis of GPI-anchored proteins
- Vitamin B5 (pantothenate) metabolism
|
|
|